Fecal microbiota transplantation combined with prebiotics ameliorates ulcerative colitis in mice

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Rubin DT, Ananthakrishnan AN, Siegel CA et al. ACG Clinical Guideline: ulcerative colitis in adults. Am. J. Gastroenterol. 114(3), 384–413 (2019).
  MedlineGoogle Scholar
• 2. Lima SF, Gogokhia L, Viladomiu M et al. Transferable immunoglobulin A-coated Odoribacter splanchnicus in responders to fecal microbiota transplantation for ulcerative colitis limits colonic inflammation. Gastroenterology 162(1), 166–178 (2022).
  Medline CASGoogle Scholar
• 3. Qiu P, Ishimoto T, Fu L et al. The gut microbiota in inflammatory bowel disease. Front. Cell. Infect. Microbiol. 12, 733992 (2022).
  Medline CASGoogle Scholar
• 4. Ianiro G, Bibbo S, Porcari S et al. Fecal microbiota transplantation for recurrent C. difficile infection in patients with inflammatory bowel disease: experience of a large-volume European FMT center. Gut Microbes 13(1), 1994834 (2021). •• Fecal microbiota transplantation appears to be highly effective and safe in patients with inflammatory bowel disease and recurrent Clostridioides difficile infection and is likely not only to eradicate C. difficile but also to improve disease activity of inflammatory bowel disease.
  MedlineGoogle Scholar
• 5. Sachs RE, Edelstein CA. Ensuring the safe and effective FDA regulation of fecal microbiota transplantation. J. Law Biosci. 2(2), 396–415 (2015).
  MedlineGoogle Scholar
• 6. Gweon TG, Lee YJ, Kim KO et al. Clinical practice guidelines for fecal microbiota transplantation in Korea. J. Neurogastroenterol. Motil. 28(1), 28–42 (2022).
  MedlineGoogle Scholar
• 7. Chen M, Liu XL, Zhang YJ et al. Efficacy and safety of fecal microbiota transplantation by washed preparation in patients with moderate to severely active ulcerative colitis. J. Dig. Dis. 21(11), 621–628 (2020).
  Medline CASGoogle Scholar
• 8. Lahtinen P, Jalanka J, Mattila E et al. Fecal microbiota transplantation for the maintenance of remission in patients with ulcerative colitis: a randomized controlled trial. World J. Gastroenterol. 29(17), 2666–2678 (2023).
  Medline CASGoogle Scholar
• 9. Gibson GR, Hutkins R, Sanders ME et al. Expert consensus document: the International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat. Rev. Gastroenterol. Hepatol. 14(8), 491–502 (2017).
  MedlineGoogle Scholar
• 10. Casellas F, Borruel N, Torrejon A et al. Oral oligofructose-enriched inulin supplementation in acute ulcerative colitis is well tolerated and associated with lowered faecal calprotectin. Aliment. Pharmacol. Ther. 25(9), 1061–1067 (2007). • Oligofructose-enriched inulin was well tolerated and dyspeptic symptoms decreased significantly with active treatment.
  Medline CASGoogle Scholar
• 11. Neumer F, Urraca O, Alonso J et al. Long-term safety and efficacy of prebiotic enriched infant formula – a randomized controlled trial. Nutrients 13(4), 1276 (2021). • Supplementation with inulin-type prebiotic oligosaccharides beneficially modulates the infant gut microbiota towards higher Bifidobacterium levels during the first 6 months of life.
  Medline CASGoogle Scholar
• 12. Scholtens PA, Alliet P, Raes M et al. Fecal secretory immunoglobulin A is increased in healthy infants who receive a formula with short-chain galacto-oligosaccharides and long-chain fructo-oligosaccharides. J. Nutr. 138(6), 1141–1147 (2008).
  Medline CASGoogle Scholar
• 13. Lindsay JO, Whelan K, Stagg AJ et al. Clinical, microbiological, and immunological effects of fructo-oligosaccharide in patients with Crohn’s disease. Gut 55(3), 348–355 (2006).
  Medline CASGoogle Scholar
• 14. Swanson KS, Gibson GR, Hutkins R et al. The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of synbiotics. Nat. Rev. Gastroenterol. Hepatol. 17(11), 687–701 (2020).
  MedlineGoogle Scholar
• 15. Fujimori S, Gudis K, Mitsui K et al. A randomized controlled trial on the efficacy of synbiotic versus probiotic or prebiotic treatment to improve the quality of life in patients with ulcerative colitis. Nutrition 25(5), 520–525 (2009).
  MedlineGoogle Scholar
• 16. Bueno LR, da Silva Soley B, Abboud KY et al. Protective effect of dietary polysaccharides from yellow passion fruit peel on DSS-induced colitis in mice. Oxid. Med. Cell. Longev. 2022, 6298662 (2022).
  MedlineGoogle Scholar
• 17. Zhang W, Zou G, Li B et al. Fecal microbiota transplantation (FMT) alleviates experimental colitis in mice by gut microbiota regulation. J. Microbiol. Biotechnol. 30(8), 1132–1141 (2020).
  Medline CASGoogle Scholar
• 18. Zhang J, Fan J, Luo H et al. Alleviation of alcoholic fatty liver by Dendrobium officinale flower extracts due to regulation of gut microbiota and short-chain fatty acids in mice exposed to chronic alcohol. Foods 12, 7 (2023).
  Google Scholar
• 19. Parada Venegas D, De la Fuente MK, Landskron G et al. Short chain fatty acids (SCFAs)-mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases. Front. Immunol. 10, 277 (2019).
  MedlineGoogle Scholar
• 20. Yu EW, Gao L, Stastka P et al. Fecal microbiota transplantation for the improvement of metabolism in obesity: the FMT-TRIM double-blind placebo-controlled pilot trial. PLoS Med. 17(3), e1003051 (2020).
  MedlineGoogle Scholar
• 21. Kim MS, Kim Y, Choi H et al. Transfer of a healthy microbiota reduces amyloid and tau pathology in an Alzheimer’s disease animal model. Gut 69(2), 283–294 (2020).
  Medline CASGoogle Scholar
• 22. Costello SP, Hughes PA, Waters O et al. Effect of fecal microbiota transplantation on 8-week remission in patients with ulcerative colitis: a randomized clinical trial. JAMA 321(2), 156–164 (2019).
  MedlineGoogle Scholar
• 23. Huang C, Huang Z, Ding L et al. Fecal microbiota transplantation versus glucocorticoids for the induction of remission in mild to moderate ulcerative colitis. J. Transl. Med. 20(1), 354 (2022).
  Medline CASGoogle Scholar
• 24. Segal JP, LeBlanc JF, Hart AL. Ulcerative colitis: an update. Clin. Med. (Lond.) 21(2), 135–139 (2021).
  MedlineGoogle Scholar
• 25. Guo XY, Liu XJ, Hao JY. Gut microbiota in ulcerative colitis: insights on pathogenesis and treatment. J. Dig. Dis. 21(3), 147–159 (2020).
  MedlineGoogle Scholar
• 26. Nascimento RPD, Machado A, Galvez J et al. Ulcerative colitis: gut microbiota, immunopathogenesis and application of natural products in animal models. Life Sci. 258, 118129 (2020).
  Medline CASGoogle Scholar
• 27. Peng L, Gao X, Nie L et al. Astragalin attenuates dextran sulfate sodium (DSS)-induced acute experimental colitis by alleviating gut microbiota dysbiosis and inhibiting NF-κB activation in mice. Front. Immunol. 11, 2058 (2020).
  Medline CASGoogle Scholar
• 28. Barcena C, Valdes-Mas R, Mayoral P et al. Healthspan and lifespan extension by fecal microbiota transplantation into progeroid mice. Nat. Med. 25(8), 1234–1242 (2019).
  Medline CASGoogle Scholar
• 29. Tian Z, Liu J, Liao M et al. Beneficial effects of fecal microbiota transplantation on ulcerative colitis in mice. Dig. Dis. Sci. 61(8), 2262–2271 (2016).
  MedlineGoogle Scholar
• 30. Tatiya-Aphiradee N, Chatuphonprasert W, Jarukamjorn K. Immune response and inflammatory pathway of ulcerative colitis. J. Basic Clin. Physiol. Pharmacol. 30(1), 1–10 (2018).
  MedlineGoogle Scholar
• 31. Mu H, Bai H, Sun F et al. Pathogen-targeting glycovesicles as a therapy for salmonellosis. Nat. Commun. 10(1), 4039 (2019).
  MedlineGoogle Scholar
• 32. Burokas A, Arboleya S, Moloney RD et al. Targeting the microbiota–gut–brain axis: prebiotics have anxiolytic and antidepressant-like effects and reverse the impact of chronic stress in mice. Biol. Psychiatry 82(7), 472–487 (2017).
  Medline CASGoogle Scholar
• 33. Martyniak A, Medynska-Przeczek A, Wedrychowicz A et al. Prebiotics, probiotics, synbiotics, paraprobiotics and postbiotic compounds in IBD. Biomolecules 11, 12 (2021).
  Google Scholar
• 34. Schoemaker MH, Hageman JHJ, Ten Haaf D et al. Prebiotic galacto-oligosaccharides impact stool frequency and fecal microbiota in self-reported constipated adults: a randomized clinical trial. Nutrients 14(2), 309 (2022).
  Medline CASGoogle Scholar
• 35. Newburg DS. Human milk oligosaccharides vary among populations. Am. J. Clin. Nutr. 105(5), 1027–1028 (2017).
  MedlineGoogle Scholar
• 36. Arslanoglu S, Moro GE, Boehm G. Early supplementation of prebiotic oligosaccharides protects formula-fed infants against infections during the first 6 months of life. J. Nutr. 137(11), 2420–2424 (2007).
  Medline CASGoogle Scholar
• 37. Bruzzese E, Volpicelli M, Squeglia V et al. A formula containing galacto- and fructo-oligosaccharides prevents intestinal and extra-intestinal infections: an observational study. Clin. Nutr. 28(2), 156–161 (2009).
  Medline CASGoogle Scholar
• 38. Musilova S, Rada V, Marounek M et al. Prebiotic effects of a novel combination of galactooligosaccharides and maltodextrins. J. Med. Food 18(6), 685–689 (2015).
  Medline CASGoogle Scholar
• 39. Perez-Matute P, Iniguez M, de Toro M et al. Autologous fecal transplantation from a lean state potentiates caloric restriction effects on body weight and adiposity in obese mice. Sci. Rep. 10(1), 9388 (2020).
  Medline CASGoogle Scholar
• 40. Burrello C, Giuffre MR, Macandog AD et al. Fecal microbiota transplantation controls murine chronic intestinal inflammation by modulating immune cell functions and gut microbiota composition. Cells 8(6), 517 (2019).
  Medline CASGoogle Scholar
• 41. Wang C, Li W, Wang H et al. Saccharomyces boulardii alleviates ulcerative colitis carcinogenesis in mice by reducing TNF-alpha and IL-6 levels and functions and by rebalancing intestinal microbiota. BMC Microbiol. 19(1), 246 (2019).
  MedlineGoogle Scholar
• 42. Gomes AC, de Sousa RG, Botelho PB et al. The additional effects of a probiotic mix on abdominal adiposity and antioxidant status: a double-blind, randomized trial. Obesity (Silver Spring) 25(1), 30–38 (2017).
  Medline CASGoogle Scholar
• 43. Blaak EE, Canfora EE, Theis S et al. Short chain fatty acids in human gut and metabolic health. Benef. Microbes 11(5), 411–455 (2020).
  Medline CASGoogle Scholar
• 44. Huda-Faujan N, Abdulamir AS, Fatimah AB et al. The impact of the level of the intestinal short chain fatty acids in inflammatory bowel disease patients versus healthy subjects. Open Biochem. J. 4, 53–58 (2010).
  Medline CASGoogle Scholar
• 45. Machiels K, Joossens M, Sabino J et al. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut 63(8), 1275–1283 (2014).
  Medline CASGoogle Scholar
• 46. Changchien CH, Wang CH, Chen HL. Konjac glucomannan polysaccharide and inulin oligosaccharide ameliorate dextran sodium sulfate-induced colitis and alterations in fecal microbiota and short-chain fatty acids in C57BL/6J mice. Biomedicine (Taipei) 11(3), 23–30 (2021).
  MedlineGoogle Scholar
• 47. Ji J, Shu D, Zheng M et al. Microbial metabolite butyrate facilitates M2 macrophage polarization and function. Sci. Rep. 6, 24838 (2016).
  Medline CASGoogle Scholar
• 48. Sokol H, Pigneur B, Watterlot L et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc. Natl Acad. Sci. USA 105(43), 16731–16736 (2008).
  Medline CASGoogle Scholar
• 49. Wang C, Shoji H, Sato H et al. Effects of oral administration of Bifidobacterium breve on fecal lactic acid and short-chain fatty acids in low birth weight infants. J. Pediatr. Gastroenterol. Nutr. 44(2), 252–257 (2007).
  Medline CASGoogle Scholar
• 50. Vemuri R, Gundamaraju R, Shinde T et al. Lactobacillus acidophilus DDS-1 modulates intestinal-specific microbiota, short-chain fatty acid and immunological profiles in aging mice. Nutrients 11(6), 1297 (2019).
  Medline CASGoogle Scholar
• 51. Balakrishnan B, Luckey D, Bodhke R et al. Prevotella histicola protects from arthritis by expansion of allobaculum and augmenting butyrate production in humanized mice. Front. Immunol. 12, 609644 (2021).
  Medline CASGoogle Scholar